NKGen Biotech Announced The Dosing Of The First Patient In Its Phase 1/2a Trial Evaluating SNK01, A Cryopreserved Autologous, Non-Genetically Modified NK Cell Therapy Product With Enhanced Cytotoxicity And Activating Receptor Expression

NKGen Biotech Inc Ordinary Shares +3.33% Pre

NKGen Biotech Inc Ordinary Shares





0.00% Pre

NKGen Biotech's autologous clinical program product candidate, SNK01, demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer's Disease ("AD") in its Phase 1 dose-escalation safety trial.


SNK01 consists of a non-genetically modified NK cell product with enhanced cytotoxicity and activating receptor expression for the treatment of moderate AD.

Initial patient in this Phase 1/2a trial received 6 billion cells, 50% more than the maximum dosing from the Phase 1 trial.

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via